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Abstract
Objectives To predict treatment effects for individual patients based on
data from randomised trials, taking rosuvastatin treatment in the primary
prevention of cardiovascular disease as an example, and to evaluate
the net benefit of making treatment decisions for individual patients
based on a predicted absolute treatment effect.
Setting As an example, data were used from the Justification for the
Use of Statins in Prevention (JUPITER) trial, a randomised controlled
trial evaluating the effect of rosuvastatin 20 mg daily versus placebo on
the occurrence of cardiovascular events (myocardial infarction, stroke,
arterial revascularisation, admission to hospital for unstable angina, or
death from cardiovascular causes).
Population 17 802 healthy men and women who had low density
lipoprotein cholesterol levels of less than 3.4 mmol/L and high sensitivity
C reactive protein levels of 2.0 mg/L or more.
Methods Data from the Justification for the Use of Statins in Prevention
trial were used to predict rosuvastatin treatment effect for individual
patients based on existing risk scores (Framingham and Reynolds) and
on a newly developed prediction model. We compared the net benefit
of prediction based rosuvastatin treatment (selective treatment of patients
whose predicted treatment effect exceeds a decision threshold) with the
net benefit of treating either everyone or no one.
Results The median predicted 10 year absolute risk reduction for
cardiovascular events was 4.4% (interquartile range 2.6-7.0%) based
on the Framingham risk score, 4.2% (2.5-7.1%) based on the Reynolds
score, and 3.9% (2.5-6.1%) based on the newly developed model
(optimal fit model). Prediction based treatment was associated with more
net benefit than treating everyone or no one, provided that the decision
threshold was between 2% and 7%, and thus that the number willing to
treat (NWT) to prevent one cardiovascular event over 10 years was
between 15 and 50.
Conclusions Data from randomised trials can be used to predict
treatment effect in terms of absolute risk reduction for individual patients,
based on a newly developed model or, if available, existing risk scores.
The value of such prediction of treatment effect for medical decision
making is conditional on the NWT to prevent one outcome event.
Trial registration number Clinicaltrials.gov NCT00239681.
Introduction
Usually the results of trials are implemented in clinical practice
by either treating all patients (in the case of a positive trial result)
or treating no one (in the case of a negative trial result),
expecting the treatment effect for every patient to be similar to
the average treatment effect in the original trial. Clinicians
intuitively know that this idea is oversimplified because in
reality some patients benefit more than average from treatment,
whereas others do not or may even be harmed.1-6
The direct translation of trial results to individual patients in
clinical practice is, however, complicated by some important
limitations. The treatment effects of randomised trials are
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typically expressed in terms of relative risks or hazard ratios at
a group level—that is, treatment versus control. Yet treatment
that is associated with a considerable reduction in relative risk
will still result in a modest absolute effect when the incidence
rate of the disease is low. Absolute risk reduction is usually
more informative because it combines the relative risk reduction
and the incidence rate of the disease outcome.1 2 The absolute
risk reduction is sometimes expressed in trial reports as the
number needed to treat (NNT). Still, implicit in the use of
estimates at group level is that all patients are at average risk
and all have the same likelihood of response to treatment.
Usually at least one of these two assumptions is untrue because
the expected absolute risk reduction resulting from treatment
often depends on the characteristics of individual patients.1-6
Although prespecified subgroup analyses take a step towards
identifying those characteristics of patients that modify the
treatment effect, some important limitations are retained. In
subgroup analyses the study cohort is typically divided according
to the presence or absence of a single patient characteristic such
as diabetes, age (below or above a certain limit), or sex, and the
effect of the intervention is presented accordingly. However,
these univariable analyses do not fully incorporate all available
patient characteristics and are less well powered but still return
relative, rather than absolute, average effect measures at a group
level.2-4
Amore comprehensive approach towardsmakingwell informed
decisions about treatment is to predict the treatment effect for
individual patients based on all relevant characteristics
together.1-5 7 Although not yet widely appreciated, data from
randomised controlled trials usually provide an opportunity to
develop models for the prediction of a treatment effect on the
basis of individual patient characteristics.1 5 Such models can
enable clinicians to estimate a treatment effect for individual
patients in terms of absolute risk reduction for the disease of
interest. This can be done before the start of intended treatment,
and therefore decisions about treatment can be based on such
predictions.4 Moreover, individualised predictions of treatment
effect provide an opportunity to determine which implications
the results of randomised trials should have in clinical practice.6
Making treatment decisions on the basis of a predicted treatment
effect for individual patients may in some situations result in
more net benefit on a group level than treating all patients (in
the case of a positive trial result) or treating no one (in the case
of a negative trial result). Although this approach is occasionally
used in the research of cancer8-10 and cardiovascular disease,11-13
the full potential has yet to be recognised by both researchers
and clinicians.
We developed and evaluated methods for predicting treatment
effect using rosuvastatin in individual patients in a primary
prevention setting based on data from the Justification for the
Use of Statins in Prevention trial.14 This study was a randomised,
double blind, placebo controlled, multicentre trial that showed
on average a 44% relative risk reduction inmajor vascular events
in those treated with rosuvastatin. As the trial was carried out
in a primary prevention cohort at moderate absolute risk for
cardiovascular disease, the overall treatment effect was modest
for average absolute risk reduction. Therefore the trial represents
a typical situation in which the prediction of treatment effect
can be used to identify those who will benefit from treatment.
We predicted treatment effects for individual patients based on
data from randomised trials, taking rosuvastatin treatment in
primary prevention of cardiovascular disease as an example,
and evaluated the net benefit of making treatment decisions for
individual patients based on predicted absolute treatment effect.
Methods
The design, rationale, and outcomes of the Justification for the
Use of Statins in Prevention trial are described in detail
elsewhere.14-16 Briefly, the trial evaluated the effect of
rosuvastatin 20 mg daily compared with placebo on the
occurrence of myocardial infarction, stroke, arterial
revascularisation, admission to hospital for unstable angina, or
death from cardiovascular causes among 17 802 apparently
healthy men and women who had low density lipoprotein
cholesterol levels of less than 3.4 mmol/L (130mg/dL) and high
sensitivity C reactive protein levels of 2.0 mg/L or more. After
a median follow-up of 1.9 years the hazard ratio for occurrence
of the primary end point was 0.56 (95% confidence interval
0.46 to 0.69), favouring rosuvastatin.14 Univariable subgroup
analyses (for example, for age, sex, smoking status, ethnicity,
and Framingham risk score) showed no significant deviations
from this effect size.
Estimating treatment effects for individual
patients
We estimated the baseline 10 year risk for cardiovascular events
(myocardial infarction, stroke, arterial revascularisation,
admission to hospital for unstable angina, or death from
cardiovascular causes) for individual patients if untreated, using
the existing Framingham risk score17 and the Reynolds risk
score, without prior updating or refitting of the coefficients (see
box).18 19Based on the assumption that treatment effect increases
linearly with baseline risk (fig 1⇓), we estimated the patient’s
residual risk when given treatment by multiplying baseline risk
by the overall relative effect measure (relative risk or hazard
ratio) from the original trial report. Consequently the estimated
absolute risk reduction achieved by treatment with rosuvastatin
for 10 years (10 year treatment effect) is equal to the difference
between these two [individual treatment effect=(1−overall
relative effect measure from trial)×baseline risk derived from
an existing prediction model].
Alternatively we developed a new prediction model (optimal
fit model) based on trial data only (see web extra appendix 1).
A theoretical advantage of this strategy over using existing risk
scores is that the model may be better calibrated to the
population of interest. Furthermore, such a model is not based
on the assumption that treatment effect increases linearly with
baseline risk: modification of the treatment effect by patient
characteristics can be tested and, if significant, included in the
model. Importantly, even in the absence of subgroup effects
defined by univariable characteristics, a multivariable adjusted
prediction model may contain such modifications of treatment
effect. In situations where no existing prediction models are
available, developing a new prediction model may be the only
option.
Performance of the prediction models
We assessed the calibration of the predictions based on the
Framingham risk score, the Reynolds risk score, and the optimal
fit model. To do this we plotted the observed Kaplan-Meier
survival for cardiovascular events at two years within 10ths of
the predicted survival against the mean predicted two year
survival of each 10th and by the P value derived from the
Hosmer-Lemeshow test. Based on the assumption that the hazard
rate is constant and thus survival is exponential over time we
derived two year risk estimates of the Framingham risk score
and the Reynolds risk score from the 10 year predicted risks.
Discrimination was assessed by calculation of the C statistic.
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Prediction of treatment effect for individual patients
10 year treatment effect (absolute risk reduction)=baseline risk without treatment−residual risk with rosuvastatin treatment
Baseline 10 year absolute risk for cardiovascular events (%) without treatment
Framingham risk score based method: risk as calculated from the Framingham risk score, published in the Adult
Treatment Panel III guidelines17
Reynolds risk score basedmethod: risk as calculated from the Reynolds risk score, derived for women from theWomen’s
Health Study18 and for men from the Physicians Health Study19
Optimal fit model*:
(1−0.985433(5×exp[B]))×100%, where:
B=0.09379363 × age in years + 3.34656382 (if male) − 0.03698750 × age in years (if male) + 0.81823698 (if current
smoker) + 0.54045383 (if using blood pressure lowering drugs) + 0.60281674 (if family history of premature coronary
heart disease) − 6.9932
Residual 10 year absolute risk for cardiovascular events (%) with rosuvastatin treatment
Framingham risk score: 0.56 × baseline 10 year absolute risk for cardiovascular events (%) without treatment
Reynolds risk score: 0.56 × baseline 10 year absolute risk for cardiovascular events (%) without treatment
Optimal fit model*:
(1−0.985433(5×exp[B])×100%, where:
B=0.09379363 × age in years + 3.34656382 (if male) − 0.03698750 × age in years (if male) + 0.81823698 (if current
smoker) + 0.54045383 (if using blood pressure lowering drugs) + 0.00932154 (if family history of premature coronary
heart disease) − 7.484613
*Treatment effect of rosuvastatin expressed in optimal fit model for residual risk as different coefficient for family history
of premature coronary heart disease and different constant subtraction factor
Assessment of net benefit
We determined the value of individualised predictions of
treatment effect for medical decision making using the
previously described net benefit assessment method.5 This
method calculates the impact of different treatment strategies
using the event rates and the treatment rates in study participants.
We considered the following approaches to rosuvastatin
treatment of patients without previous vascular disease or
diabetes mellitus and low levels of low density lipoprotein
cholesterol: treat all, treat no one, or treat based on
prediction—that is, the selective treatment of patients whose
predicted treatment effect exceeds a decision threshold. To
facilitate clinical interpretation we extrapolated the observed
event rates at two years to 10 years (see web extra appendix 2
for an explanation of the net benefit assessment method, with
a sample calculation).
The decision threshold used for prediction based treatment
represents the estimated harms of treatment, such as excess risk
for adverse reactions, monetary costs, and the discomfort of
sustaining treatment (fig 1). Notably, estimation of the harms
of treatment is also needed to calculate and interpret the net
benefit of one treatment strategy over another. One research
team proposed to estimate the decision threshold by weighing
the harms of treatment against the harms of an outcome event.5 20
For example, if the harms of a cardiovascular event are assumed
to be 20 times worse than those of rosuvastatin treatment for
10 years, the appropriate decision threshold is 5% (1 divided
by 20), and only those individuals whose predicted 10 year
absolute treatment effect exceeds 5% should be advised to start
rosuvastatin treatment. Usually, however, the level of the
decision threshold is not discussed, but rather the maximum
acceptable number needed to treat (NNT). For this purpose we
propose to rename the NNT that is associated with clinical
equipoise as the number willing to treat (NWT). If rosuvastatin
treatment of 20 people for 10 years is assumed to be exactly as
harmful as one outcome event (for example, a case ofmyocardial
infarction), doctors would be willing to treat up to 20 patients
to prevent one event, therefore the NWT is 20. The NWT is the
inverse of the decision threshold but generally more intuitive
to clinicians.
The main harms resulting from rosuvastatin treatment include
monetary costs and the discomfort of taking the drug daily,
since multiple trials, including the Justification for the Use of
Statins in Prevention trial, show that treatment with rosuvastatin
20 mg daily is not associated with an increased risk of adverse
reactions, except for a small increase in the probability of newly
diagnosed diabetes. Moreover, particularly among those with
impaired fasting glucose (the group most likely to develop
diabetes), large risk reductions in macrovascular disease are
observed. None the less, the appropriate decision threshold is
subjective and may differ between countries and over time. For
this reason we did not make any assumptions about the severity
of the harms associated with treatment but calculated the net
benefit for a range of values of NWT. To graphically represent
the net benefit assessment results for this range of values of
NWT in a decision curve, we applied locally weighted scatter
plot smoothing.5 20
Analyses were done using open source statistical software, R
version 2.10.0 (R Foundation for Statistical Computing, www.
R-project.org).
Results
Table 1⇓ shows the baseline clinical characteristics of the
Justification for the Use of Statins in Prevention cohort. Overall,
140 events were observed in the rosuvastatin treated group (8853
participants) and 251 in the placebo treated group (8857
participants). Data related to 92 participants were excluded from
the analyses owing to missing data for one or more predictor
variables. The Kaplan-Meier survival curves of both treatment
groups had been published before and did not show any
remarkable aberrations at the two year follow-up.14
The box shows the models used for the prediction of the
treatment effect from using rosuvastatin. The final optimal fit
model contains terms for age, sex, age-sex interaction, smoking,
blood pressure lowering drugs, and family history of premature
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myocardial infarction. Importantly, the study population was
selected to have low density lipoprotein cholesterol levels of
less than 3.4 mmol/L (130 mg/dL) and high sensitivity C
reactive protein levels of 2.0 mg/L or more. This might have
contributed to the fact that neither lipids nor high sensitivity C
reactive protein were selected in the final optimal fit model.
The model contained one treatment-covariate interaction: a
family history of premature coronary heart disease was the only
patient characteristic that affected the rosuvastatin treatment
effect.
Calibration and discrimination of all three prediction methods
were moderate. The C statistic of the Framinghammodel based
predictions in the Justification for the Use of Statins in
Prevention cohort was 0.65 (95% confidence interval 0.62 to
0.68), almost equal to the C statistic of the predictions based on
the Reynolds model (0.66, 0.63 to 0.69). As expected, the
optimal fit model performed a little better because discrimination
was tested in the same cohort fromwhich it was developed. The
C statistic was 0.71 (0.68 to 0.74). The Reynolds risk score
somewhat overestimated risk for cardiovascular events within
the highest 10th of predicted risk, resulting in some lack of fit
as evidenced by a significant Hosmer-Lemeshow statistic (fig
2⇓).
The Framingham risk score, the Reynolds risk score, and the
optimal fit model can be applied to calculate the predicted 10
year treatment effect of using rosuvastatin for two patient
scenarios (table 2⇓). Likewise, the 10 year treatment effect was
predicted for every individual within the Justification for the
Use of Statins in Prevention cohort, the distributions of which
are presented in figure 3⇓. Coloured bars indicate how the
predicted 10 year treatment effect of the two patient scenarios
relate to that of all participants within the study cohort. The
median predicted 10 year absolute risk reduction for all
participants in the Justification for the Use of Statins in
Prevention trial according to the Framingham based model was
4.4% (interquartile range 2.6-7.0%), the Reynolds based model
was 4.2% (2.5-7.1%), and the optimal fit model was 3.9%
(2.5-6.1%).
Net benefit assessment
Web extra appendix 2 shows an example of a net benefit
calculation. In this example the net benefit of prediction based
treatment using the Framingham risk score is compared with
the net benefit of treating all patients, assuming that 20 is the
appropriate NWT. Similar calculations were carried out for a
range of values for NWT and also for prediction based treatment
using the Reynolds risk score and optimal fit model. The net
benefit of treating no one serves as a reference and is equal to
zero. The net benefit of the other strategies represents the
resulting decrease in the event rate minus the cost of treatment.
Treatment of all patients is more beneficial than treating no one
if the NWT is high (little harm, treat even at low risk) but not
if the NWT is low (considerable harm, treat at high risk only;
table 3⇓ and fig 4⇓). If the NWT is about 20, then the benefits
of treating all patients and treating no one are equivalent (zero).
Prediction based treatment is associated with equal net benefit
as treating all patients for high values of NWT and the net
benefit curves of prediction based treatment converge to zero
(treat no one) for lower values of NWT (fig 4). For a range of
NWT (between about 15 and 50), prediction based treatment is
the preferred strategy of choice. Notably, the net benefits of
prediction based treatment based on the optimal fit model and
the Framingham or Reynolds risk score were similar. Therefore
the assumption that treatment effect increases linearly with
baseline cardiovascular risk (fig 1) appears to be true in this
example.
Interpreting the size of the net benefit advantage of one strategy
over another is complex. One study proposed to imagine that
the same net benefit value was achieved by an infallible
prediction model that identifies a certain percentage of people
as being not at risk for the outcome and thus not in need of
treatment. Such a fictitious infallible prediction model reduces
the treatment rate without increasing the event rate.5 If this
method is applied to the present data this means that for a NWT
of 30, the net benefit advantage of prediction based treatment
(mean net benefit over all three methods is 0.0228) over treating
all patients (net benefit is 0.0165), is equivalent to that of
treatment by a fictitious infallible prediction model that reduces
the treatment rate by 19% without increasing the event rate.
Likewise, if the NWT is 20, the mean advantage of prediction
based treatment over treating all patients is equal to a 16%
reduction of the treatment rate.
Translation to clinical practice
Figure 5⇓ illustrates how the findings could be translated to
clinical practice. Treatment of all patients is the strategy of
choice if the 10 year NWT is 50 or more. Treat none is
preferable if the 10 year NWT is 15 or fewer. If the NWT is
between 15 and 50, prediction based treatment results in most
net benefit. Because the three prediction methods resulted in
similar net benefit, treatment prediction based on existing risk
scores is most appropriate in clinical practice. These risk scores
are already externally validated and more easily implemented.
This means that if, for example, the 10 year NWT to prevent
one cardiovascular event is 20, patients with a baseline (for
example, Framingham score or Reynolds score) risk of 11.4%
or more (95% confidence interval 9.3% to 16.1%) benefit from
treatment. Likewise, if the 10 year NWT is 30, patients with a
baseline risk of 7.6% or more (6.2% to 10.8%) benefit from
treatment. These findings do not contradict the current
guidelines, which also recommend treating those whose risk
for cardiovascular events exceeds a certain threshold.21However,
our findings do suggest that the optimal treatment threshold
may be lower than is often assumed.
Discussion
The direct translation of results of trials to individual patients
in clinical practice is often difficult because not all respond to
treatment similar to the average patient enrolled in a trial. This
is because the effect of treatment often depends on the
characteristics of individual patients. In the present study we
have shown how data from randomised clinical trials can be
used to predict absolute treatment effects for individual patients,
taking patient characteristics into account. In addition, we have
assessed the added value of such predictions for medical
decision making.
Implementation of an individualised prediction of treatment
effect in clinical practice is not necessarily complicated. Several
prediction rules are already available for estimating baseline
risk for vascular events in primary prevention—for example,
the Framingham risk score and Reynolds risk score. The
example from the Justification for the Use of Statins in
Prevention trial shows that estimation of an individual treatment
effect can be as easy as multiplying the individual baseline risk,
as estimated from the Framingham risk score or the Reynolds
risk score, by the average relative treatment effect from the trial
report. If, however, risk scores are not yet available in a certain
area of medicine, a new prediction model to estimate individual
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treatment effect can be developed from the trial data. The
methods described in this paper can thus be applied to various
medical specialties. Online calculators and integration of
prediction models in electronic patient record systems could
facilitate the widespread use of prediction of treatment effect
in clinical practice. The trial example used in this article also
shows that even when discrimination and calibration of a
prediction model are moderate, the net benefit of treatment
assignment according to prediction can still be superior to both
treating all patients within the study domain and treating no one
for a certain range of NWT (in this example between about 15
and 50).
Prediction of treatment effect for individual patients may enable
doctors to practise individualised medicine in an evidence based
manner. It could help to make better informed treatment
decisions and perhaps motivate patients to adhere to treatment.
Presentation of the net benefit of all possible strategies of
treatment assignment for a spectrum of NWT is useful in this
respect because the NWT possibly varies with patient and
provider preferences. This is especially true when treatment is
associated with important adverse reactions. For example,
treatment with tissue plasminogen activator for acute myocardial
infarction is associated with an increased risk for intracranial
haemorrhage that also varies according to individual patient
characteristics.6 13 If patients have difficulties understanding the
concept of risk, the predicted individual treatment effect
(expressed in terms of absolute risk reduction) can be expressed
as a NNT (the number of similar patients that needs to be treated
to prevent one outcome event; table 2), which might be more
intuitive, and this can be compared to the appropriate NWT.
Prediction of treatment effect for individual patients might also
facilitate the work of practice guideline committees that aim to
make well informed decisions about indications for treatment
on a group level. When the trial results are presented using the
methods presented in this paper, the remaining issue that
guideline committees need to focus on is the appropriate NWT.
The NWT is estimated by weighing the total harms of treatment
(for example, adverse reactions, monetary costs, discomfort of
sustaining treatment) against the harms of the outcome event
of interest (cardiovascular event). For any given NWT three
possible treatment strategies must be considered: treat everyone,
treat no one, or treat based on prediction (selective treatment of
patients whose predicted treatment effect exceeds a decision
threshold). When the NWT is agreed on, the trial results can be
used to estimate the net benefit of each strategy (table 3 and fig
4) and to determine the optimal treatment strategy (fig 5). The
treatment strategy with the highest net benefit for the appropriate
value of NWT results in the most favourable trade-off between
treatment rate and event rate. Applying this strategy in clinical
practice leads to more selective treatment of patients who will
benefit from treatment.
Previously, risk stratified reporting of trial results was proposed
as a method for presenting heterogeneity of treatment effects
in trials.3 7 In line with this, the relative risk and NNT for
participants of the Justification for the Use of Statins in
Prevention trial within subgroups of estimated baseline risk
were published earlier.22-24 Stratified analysis of treatment effects
in subgroups of the total study cohort may, however, lead to
imprecision owing to loss of statistical power. Moreover,
existing risk scores are not available for many diseases,
invalidating the risk stratified approach. Also, risk based
stratificationmay still obscure important modification of relative
treatment effect that can be discovered or excluded (as in the
Justification for the Use of Statins in Prevention trial example)
by a multivariate model for predicting treatment effect based
on trial data. Also, the cut-off values for defining subgroups of
estimated baseline risk are usually predefined, whereas the
methods shown in this paper allow searching for the treatment
threshold that is associated with maximum net benefit.
Although data from clinical trials have been used before to
predict treatment effects for individual patients, evidence
supporting the added value of individualised prediction of
treatment effect for clinical practice has been sparse.8-13
Expensive and long lasting impact trials were needed to show
the benefit of prediction based treatment.25 In this article we
show that the net benefit assessment methods, described
previously, provide a more efficient and readily available
opportunity for evaluating the potential net benefit of prediction
based treatment and for determining implications of
contemporary trial results for clinical practice.5 This report also
shows that the added value of individualised prediction of
treatment effect for medical decision making may not be
universal but instead is conditional on the NWT.
Limitations and challenges of the study
Limitations of using trial data for individualised predictions of
treatment effect generally include short and variable follow-up
times, whereas meaningful predictions of cardiovascular event
risk usually comprise a 10 year period. This is particularly true
for the Justification for the Use of Statins in Prevention trial
because the study was discontinued early, but few clinical trials
have a follow-up period as long as 10 years either. Thus the
predictions and observations usually need to be extrapolated.
Furthermore, similar to conventional trial reports,
generalisability of the results may be problematic. Trial
participants were often selected on the basis of strict eligibility
criteria and are healthier and more compliant to treatment than
are patients in clinical practice.6 In this example, the results
apply to patients without manifest vascular disease or diabetes,
but additional eligibility criteria of the trial were low levels of
low density lipoprotein cholesterol and increased levels of high
sensitivity C reactive protein. Hence application of trial based
predictions of treatment effect to the general population may
be suboptimal. This is especially true for newly fit models
because important risk factors (such as low density lipoprotein
cholesterol and high sensitivity C reactive protein in our
example) may not be included in the prediction model if all trial
participants had similar characteristics.
Apart from these practical constraints, many feel reluctant to
interpret the implications of subgroup analyses let alone
multivariate prediction of treatment effect, because
over-accuracy and chance findings may occur.26 Predictions of
treatment effect should therefore be based on existing risk scores
developed in external data when possible.2 7 Yet even when
validated risk scores are available, as in our example, developing
a new prediction model fit to the trial data can help to confirm
the assumption that treatment effect increases linearly with
baseline risk (fig 1). Moreover, it should be stressed that the
estimated treatment effects in prediction models originating
from randomised trials are not subject to confounding bias,
because treatment was allocated randomly in the study
population. Over-fitting can be minimised by careful and
preferably prespecified selection of candidate predictors and
shrinkage of the model coefficients when needed. Web extra
appendix 3 summarises considerations that need to be taken
into account when applying the methods described in this paper
to other trial datasets.
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Conclusions
Data from randomised trials can be used to predict treatment
effect in terms of absolute risk reduction for individual patients
before the start of intended treatment. Predictions could be based
on existing risk scores, if available, or a newly developedmodel.
The value of such prediction of treatment effect for medical
decision making is conditional on the NWT to prevent one
outcome event. Prediction based treatment may result in positive
net benefit for a range of NWT, even when model calibration
and discrimination are moderate. The methods shown in this
paper could therefore become a routine part of reporting clinical
trials and be used in everyday clinical practice.
Contributors: JAND designed and carried out the data analyses,
interpreted the results, and drafted the manuscript. FLJV conceived the
research question, designed the data analyses, interpreted the results,
and revised the manuscript for important intellectual content. PMR
conceived the research question, collected the data, designed the data
analyses, interpreted the results, revised the manuscript for important
intellectual content, and is guarantor for the validity of the data and
analyses. AMJW and NPP designed the data analyses, interpreted the
results, and revised the manuscript for important intellectual content.
EWS and YvdG conceived the research question, designed the data
analyses, interpreted the results, and revised the manuscript for
important intellectual content. NRC conceived the research question,
collected the data, designed the data analyses, interpreted the results,
and revised the manuscript for important intellectual content.
Funding: The Justification for the Use of Statins in Prevention was an
investigator initiated trial. The sponsor of the study collected the trial
data and monitored the study sites but had no role in the conduct of the
analyses or drafting of the report. All statistical analyses were done by
the investigators.
Competing interests: All authors have completed the ICMJE uniform
disclosure form at www.icmje.org/coi_disclosure.pdf (available on
request from the corresponding author) and declare: PMR is the principal
investigator of the investigator initiated Justification for the Use of Statins
in Prevention trial, which was funded by AstraZeneca (Wilmington,
Delaware). PMR received grant support from Novartis and Roche;
consulting fees from Siemens Medical Systems, ISIS, and Vascular
Biogenetics; and is listed as a co-inventor on patents held by the
Brigham and Women’s Hospital that relate to the use of inflammatory
biomarkers in cardiovascular disease that have been licensed to
Siemens Medical Systems (Erlangen, Germany) and AstraZeneca.
FLJV’s department receives grant support fromMerck, the Netherlands
Organisation for Health Research and Development, and the Catharijne
Foundation Utrecht; and speaker fees from Merck and AstraZeneca.
JAND, AMJW, NPP, EWS, YvdG, and NRC have no relationships with
industry that might have an interest in the submitted work in the previous
three years. All authors have no non-financial interests that may be
relevant to the submitted work.
Ethical approval: The protocol for the Justification for the Use of Statins
in Prevention trial was approved by the local institutional review boards
at each participating centre. All study participants provided written
informed consent before taking part.
Data sharing: No additional data available.
1 Glasziou PP, Irwig LM. An evidence based approach to individualising treatment. BMJ
1995;311:1356-9.
2 Hayward RA, Kent DM, Vijan S, Hofer TP. Multivariable risk prediction can greatly enhance
the statistical power of clinical trial subgroup analysis. BMCMed Res Methodol 2006;6:18.
3 Kent DM, Hayward RA. Limitations of applying summary results of clinical trials to individual
patients: the need for risk stratification. JAMA 2007;298:1209-12.
4 Rothwell PM. Can overall results of clinical trials be applied to all patients? Lancet
1995;345:1616-9.
5 Vickers AJ, Kattan MW, Daniel S. Method for evaluating prediction models that apply the
results of randomized trials to individual patients. Trials 2007;8:14.
6 Kravitz RL, Duan N, Braslow J. Evidence-based medicine, heterogeneity of treatment
effects, and the trouble with averages. Milbank Q 2004;82:661-87.
7 Kent DM, Rothwell PM, Ioannidis JP, Altman DG, Hayward RA. Assessing and reporting
heterogeneity in treatment effects in clinical trials: a proposal. Trials 2010;11:85.
8 Gill S, Loprinzi CL, Sargent DJ, Thome SD, Alberts SR, Haller DG, et al. Pooled analysis
of fluorouracil-based adjuvant therapy for stage II and III colon cancer: who benefits and
by how much? J Clin Oncol 2004;22:1797-806.
9 Loprinzi CL, Thome SD. Understanding the utility of adjuvant systemic therapy for primary
breast cancer. J Clin Oncol 2001;19:972-9.
10 Steyerberg EW, Homs MY, Stokvis A, Essink-Bot ML, Siersema PD. Stent placement or
brachytherapy for palliation of dysphagia from esophageal cancer: a prognostic model to
guide treatment selection. Gastrointest Endosc 2005;62:333-40.
11 Rothwell PM, Warlow CP. Prediction of benefit from carotid endarterectomy in individual
patients: a risk-modelling study. European Carotid Surgery Trialists’ Collaborative Group.
Lancet 1999;353:2105-10.
12 Kent DM, Hayward RA, Griffith JL, Vijan S, Beshansky JR, Califf RM, et al. An
independently derived and validated predictive model for selecting patients with myocardial
infarction who are likely to benefit from tissue plasminogen activator compared with
streptokinase. Am J Med 2002;113:104-11.
13 Califf RM, Woodlief LH, Harrell FE Jr, Lee KL, White HD, Guerci A, et al. Selection of
thrombolytic therapy for individual patients: development of a clinical model. GUSTO-I
Investigators. Am Heart J 1997;133:630-9.
14 Ridker PM, Danielson E, Fonseca FA, Genest J, Gotto AM Jr, Kastelein JJ, et al.
Rosuvastatin to prevent vascular events in men and women with elevated C-reactive
protein. N Engl J Med 2008;359:2195-207.
15 Ridker PM. Rosuvastatin in the primary prevention of cardiovascular disease among
patients with low levels of low-density lipoprotein cholesterol and elevated high-sensitivity
C-reactive protein: rationale and design of the JUPITER trial.Circulation 2003;108:2292-7.
16 Ridker PM, Fonseca FA, Genest J, Gotto AM, Kastelein JJ, Khurmi NS, et al. Baseline
characteristics of participants in the JUPITER trial, a randomized placebo-controlled
primary prevention trial of statin therapy among individuals with low low-density lipoprotein
cholesterol and elevated high-sensitivity C-reactive protein. Am J Cardiol
2007;100:1659-64.
17 National Cholesterol Education Program. Executive summary of the third report of the
National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation,
and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA
2001;285:2486-97.
18 Ridker PM, Buring JE, Rifai N, Cook NR. Development and validation of improved
algorithms for the assessment of global cardiovascular risk in women: the Reynolds risk
score. JAMA 2007;297:611-9.
19 Ridker PM, Paynter NP, Rifai N, Gaziano JM, Cook NR. C-reactive protein and parental
history improve global cardiovascular risk prediction: the Reynolds risk score for men.
Circulation 2008;118:2243-51.
20 Vickers AJ, Elkin EB. Decision curve analysis: a novel method for evaluating prediction
models. Med Decis Making 2006;26:565-74.
21 National Institute for Health and Clinical Excellence. Technology appraisal 94: statins for
the prevention of cardiovascular events. 2006. www.nice.org.uk/TA094.
22 Ridker PM, Macfadyen JG, Nordestgaard BG, Koenig W, Kastelein JJ, Genest J, et al.
Rosuvastatin for primary prevention among individuals with elevated high-sensitivity
c-reactive protein and 5% to 10% and 10% to 20% 10-year risk. Implications of the
Justification for Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin
(JUPITER) trial for “intermediate risk.” Circ Cardiovasc Qual Outcomes 2010;3:447-52.
23 Ridker PM, MacFadyen JG, Fonseca FA, Genest J, Gotto AM, Kastelein JJ, et al. Number
needed to treat with rosuvastatin to prevent first cardiovascular events and death among
men and women with low low-density lipoprotein cholesterol and elevated high-sensitivity
C-reactive protein: justification for the use of statins in prevention: an intervention trial
evaluating rosuvastatin (JUPITER). Circ Cardiovasc Qual Outcomes 2009;2:616-23.
24 Koenig W, Ridker PM. Rosuvastatin for primary prevention in patients with European
systematic coronary risk evaluation risk >=5% or Framingham risk >20%: post hoc analyses
of the JUPITER trial requested by European health authorities. Eur Heart J 2011;32:75-83.
25 Selker HP, Beshansky JR, Griffith JL. Use of the electrocardiograph-based thrombolytic
predictive instrument to assist thrombolytic and reperfusion therapy for acute myocardial
infarction. A multicenter, randomized, controlled, clinical effectiveness trial. Ann Intern
Med 2002;137:87-95.
26 Sun X, Briel M, Walter SD, Guyatt GH. Is a subgroup effect believable? Updating criteria
to evaluate the credibility of subgroup analyses. BMJ 2010;340:c117.
Accepted: 12 August 2011
Cite this as: BMJ 2011;343:d5888
This is an open-access article distributed under the terms of the Creative Commons
Attribution Non-commercial License, which permits use, distribution, and reproduction in
any medium, provided the original work is properly cited, the use is non commercial and
is otherwise in compliance with the license. See: http://creativecommons.org/licenses/by-
nc/2.0/ and http://creativecommons.org/licenses/by-nc/2.0/legalcode.
No commercial reuse: See rights and reprints http://www.bmj.com/permissions Subscribe: http://www.bmj.com/subscribe
BMJ 2011;343:d5888 doi: 10.1136/bmj.d5888 Page 6 of 13
RESEARCH
What is already known on this topic
In clinical practice some patients benefit more than average from treatment, whereas others do not or may even be
harmed
Implementing trial results by treating all or no patients, expecting the treatment effect for everyone to be similar to the
average treatment effect in the original trial, may not lead to optimal benefit
What this study adds
Data from randomised trials can be used to predict treatment effect in terms of absolute risk reduction for individual
patients
Predictions could be based on existing validated risk scores, if available, or a new prediction model fit to the trial data
The value of such prediction of treatment effect for medical decision making is conditional on the number willing to treat
(NWT) to prevent one outcome event
Tables
Table 1| Baseline characteristics of participants in Justification for the Use of Statins in Prevention trial. Values are medians (interquartile
ranges) unless specified otherwise
Population (n=17 710)Characteristic
66 (60-71)Age (years)
61.8Men (%)
71.3White ethnicity (%)
15.8Current smoker (%)
11.5Family history of premature coronary heart disease (%)
1.3 (1.0-1.6)High density lipoprotein cholesterol (mmol/L)
2.8 (2.4-3.1)Low density lipoprotein cholesterol (mmol/L)
4.8 (4.4-5.2)Total cholesterol (mmol/L)
4.3 (2.9-7.1)High sensitivity C reactive protein (mg/L)
134 (124-145)Systolic blood pressure (mm Hg)
49.5Blood pressure lowering drug use (%)
28.4 (25.3-32.0)Body mass index
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Table 2| Calculation example of predicted 10 year treatment effect for two patient scenarios
Scenario 2†Scenario 1*
Variables Optimal fit modelReynolds based
Framingham
basedOptimal fit modelReynolds based
Framingham
based
2.64.3216.613.916Baseline 10 year risk for
cardiovascular disease (%)
1.62.41.15.97.89Residual risk if treated with
rosuvastatin for 10 years
(%)
1.01.90.910.66.17Predicted absolute risk
reduction (%)
1005311191614NNT (patients with similar
characteristics) (%)
NNT=number needed to treat.
Following values were the same in both scenarios: total cholesterol level 4.8 mmol /L, high density lipoprotein cholesterol level 1.3 mmol/L, low density lipoprotein
cholesterol level 2.8 mmol/L, high sensitivity C reactive protein level 4.3 mg/L, and 134 mm Hg systolic blood pressure.
*Male non-smoker aged 60 years with family history of premature coronary heart disease and taking blood pressure lowering drugs.
‡Female smoker aged 55 years with no family history of premature coronary heart disease and not taking blood pressure lowering drugs.
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Table 3| Results of net benefit assessment
Prediction based treatment net benefit (% treatment rate)
Treat all
Decision
threshold (%)NWT Optimal fit modelReynolds scoreFramingham score
0.0499 (100)0.0499 (100)0.0499 (100)0.0499≥0InfinityLittle harm:
treat even at
low risk
0.0407 (98)0.0388 (97)0.0398 (93)0.0399≥1100
0.0376 (96)0.0376 (94)0.0371 (89)0.0365≥175
0.0316 (84)0.0307 (83)0.0320 (84)0.0299≥250
0.0271 (58)0.0180 (62)0.0233 (70)0.0165≥330
0.0106 (34)0.0080 (42)0.0054 (46)−0.0001≥520
0.0058 (19)0.0081 (28)0.0030 (32)−0.0168≥715
−0.0017 (10)0.0003 (18)−0.0038 (18)−0.0335≥812Considerable
harm: treat at
high risk only
−0.0032 (6)0.0040 (12)−0.0011 (8)−0.0501≥1010
0 (0)0 (0)0 (0)−InfinityInfinity0
NWT=number willing to treat.
The net benefit of treating no one serves as a reference and is equal to zero. Positive values imply that treatment of all patients or prediction based treatment was
superior to treating no one, given the corresponding NWT.
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Figures
Fig 1 Basic concept for weighing treatment effect against harm. Treatment effect usually increases with baseline risk,
whereas harm is relatively constant for all patients. Those whose treatment effect exceeds treatment related harm (reflected
by decision threshold) benefit from treatment1
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Fig 2 Calibration plots. Predicted and observed two year event free survival for cardiovascular events within 10ths of
predicted survival using three models. P values derived from the Hosmer-Lemeshow test
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Fig 3 Distribution of predicted 10 year absolute treatment effect (absolute risk reduction) based on Framingham risk score,
Reynolds risk score, and optimal fit model, with coloured bars indicating predicted treatment effects for two different patient
scenarios. JUPITER=the Justification for the Use of Statins in Prevention trial
Fig 4 Decision curve: graphical representation of net benefit. For large values of numbers willing to treat (NWT), the net
benefit of treating all patients is about equal to the net benefit of prediction based treatment. The net benefit of treating all
patients becomes negative if the NWT is less than 20, whereas the net benefit of prediction based treatment is still positive
for a NWT of 20 and converges to zero for smaller values of NWT
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Fig 5 Implications for clinical practice. Justification for the Use of Statins in Prevention trial shows that treatment of all
patients is the strategy of choice if the 10 year number willing to treat (NWT) is 50 or more. Treating no one is preferable
if the 10 year NWT is 15 or fewer. If the NWT is between 15 and 50, prediction based treatment results in most net benefit
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